Core Viewpoint - Regeneron Pharmaceuticals, Inc. is facing a securities fraud class action following a significant drop in its stock price, which resulted in a loss of approximately $9 billion in market value due to alleged misleading statements regarding its EYLEA® product [1][5]. Group 1: Legal Issues and Investigations - Hagens Berman has initiated an investigation into Regeneron for potentially misleading investors about its marketing and reimbursement practices related to EYLEA®, urging affected investors to report their losses [2][6]. - The class action lawsuit focuses on Regeneron's compliance with regulations concerning Medicare reimbursement claims, particularly regarding EYLEA® [3]. - The complaint alleges that Regeneron made false statements and failed to disclose various practices that misrepresented the pricing and sales of EYLEA®, including undisclosed credit card fees that effectively lowered the selling price [4]. Group 2: Financial Impact - On October 31, 2024, Regeneron reported disappointing Q3 2024 financial results, with U.S. net sales for EYLEA® and EYLEA HD® increasing only 3% year-over-year, attributed to lower net selling prices and pricing pressure in the anti-VEGF category [5]. - The announcement of these financial results led to a more than 9% decline in Regeneron's share price on the same day [5].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Regeneron Pharmaceuticals, alleging that the company made materially false and misleading statements regarding its pricing practices for Eylea, which may have artificially inflated its reported sales figures [1]. Group 1: Allegations Against Regeneron - The lawsuit claims that Regeneron paid credit card fees to distributors to prevent them from charging Eylea customers more for credit card usage [1]. - These payments allegedly subsidized the prices customers paid when using credit cards, leading to a price concession that lowered Eylea's selling price [1]. - The complaint states that Regeneron's price concessions provided a competitive advantage due to retina practices being sensitive to higher prices for anti-VEGF medications [1]. - As a result of these actions, Regeneron is accused of misleadingly boosting reported Eylea sales and overstating the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 2, 2023, to October 30, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is March 10, 2025, and there is no cost or obligation to participate in the case [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Regeneron Pharmaceuticals due to allegations of misleading statements and violations of federal securities laws related to the pricing and sales of its Eylea drug [2][4][5]. Group 1: Allegations Against Regeneron - The complaint alleges that Regeneron made false and misleading statements regarding credit card fee payments to distributors, which were not disclosed as price concessions [4]. - It is claimed that these undisclosed payments led to inflated reported sales of Eylea and overstated average selling prices (ASP) reported to federal agencies, violating the False Claims Act [4][5]. - The U.S. Department of Justice filed a complaint against Regeneron, stating that the company failed to report millions in discounts, which resulted in inflated Medicare reimbursements [5]. Group 2: Financial Impact and Stock Performance - Following the DOJ announcement, Regeneron's stock price fell by $31.50, or 3.36%, closing at $904.70 on April 12, 2024, with unusually heavy trading volume [6]. - On October 31, 2024, Regeneron reported third-quarter 2024 financial results, revealing only a 3% increase in U.S. net sales for Eylea compared to the previous year, with sales of Eylea HD at $392 million, missing consensus estimates [7]. - The stock price dropped by $84.59, or 9.2%, to close at $838.20 per share on the same day, indicating a significant market reaction to the disappointing sales figures [7].

Core Points - The Regeneron Science Talent Search (STS) is the U.S.'s longest-running and most distinguished STEM competition for high school seniors, celebrating and rewarding talented young minds driving innovation through scientific exploration [1][3][10] - This year's competition features 40 finalists selected from nearly 2,500 entrants, showcasing a diverse range of research projects addressing critical societal issues [4][5][8] Group 1: Competition Overview - The 2025 Regeneron Science Talent Search is in its 84th year, identifying extraordinary young minds who blend scientific talent, curiosity, and leadership [3][10] - Finalists' research areas include species migration, crop protection, disease diagnosis using AI, and genetic therapies, reflecting their commitment to tackling pressing issues [4][5][9] Group 2: Awards and Recognition - More than $3 million in awards will be distributed, with each finalist receiving at least $25,000 and the top 10 awards ranging from $40,000 to $250,000 [7][8] - The top 300 scholars will each receive $2,000, with their schools also receiving $2,000 to support math and science programs [7][11] Group 3: Event Details - Finalists will participate in a week-long competition from March 6-12, 2025, culminating in an awards ceremony on March 11, streamed live from Washington D.C. [6][8] - The competition emphasizes the importance of nurturing STEM education and supporting accessibility for programs that promote scientific literacy and career readiness [5][6]

Core Insights - The Regeneron Science Talent Search (STS) is a prestigious STEM competition for high school seniors, celebrating its 84th year, aimed at identifying and nurturing young scientific talent [2][8] - This year's finalists represent a diverse range of research topics, including species migration, disease diagnosis using AI, and genetic therapies, showcasing their commitment to addressing critical societal issues [3][7] Group 1: Competition Overview - The STS has selected 40 finalists from nearly 2,500 entrants, highlighting the exceptional caliber of participants [4][7] - Finalists will compete for over $1.8 million in awards during a week-long event from March 6-12, 2025, with the top prize being $250,000 [5][6] - The competition emphasizes the importance of STEM education and aims to inspire future scientific leaders [4][5] Group 2: Awards and Recognition - More than $3 million in total awards will be distributed, with each finalist guaranteed at least $25,000 [6][9] - The top 300 scholars will each receive $2,000, and their schools will also receive $2,000 to support math and science programs [6][9] - Regeneron's commitment to the STS includes a 10-year, $100 million investment to enhance the awards and encourage young people to pursue STEM careers [9] Group 3: Historical Context and Impact - Alumni of the STS have achieved significant recognition, including 13 Nobel Prizes and 23 MacArthur Fellowships, demonstrating the program's long-term impact on scientific innovation [2] - The STS has a unique focus on identifying and engaging promising young scientists who can address urgent societal challenges [8]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Regeneron Pharmaceuticals, Inc. regarding a class action lawsuit alleging misleading statements and omissions related to the pricing and sales of Eylea, a primary product of the company [1]. Group 1: Allegations - The complaint alleges that Regeneron paid credit card fees to distributors to prevent them from charging Eylea customers more for credit card usage [1]. - These payments effectively subsidized the prices customers paid when using credit cards for Eylea purchases, leading to a price concession that lowered Eylea's selling price [1]. - The price concessions provided Regeneron with a competitive advantage, as retina practices were sensitive to higher prices for anti-VEGF medications [1]. - As a result of these actions, Regeneron reportedly inflated Eylea sales figures and overstated the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [1]. Group 2: Class Action Details - The class period for the lawsuit is from November 2, 2023, to October 30, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is March 10, 2025, and there is no cost or obligation to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Group 1 - A class action has been filed against Regeneron Pharmaceuticals, Inc. for allegedly misleading investors regarding its business prospects during the period from November 2, 2023, to October 30, 2024 [1][2] - The allegations include undisclosed payments made by Regeneron to distributors to subsidize credit card fees, which resulted in misleadingly reported sales figures for Eylea, a key product [2] - The complaint claims that Regeneron's failure to report these payments as price concessions led to an overstatement of the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [2] Group 2 - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by March 4, 2025 [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [4] - Robbins LLP, the firm leading the class action, has a history of advocating for shareholder rights and holding company executives accountable since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Regeneron Pharmaceuticals, alleging securities fraud and unlawful business practices related to the company's reporting of discounts to drug distributors [1][2]. Group 1: Legal Issues - The lawsuit concerns whether Regeneron and its officers engaged in securities fraud or other unlawful business practices [2]. - The U.S. Department of Justice filed a complaint against Regeneron under the False Claims Act, alleging the company failed to report millions in discounts, which inflated the Average Sales Price for its products, leading to increased Medicare reimbursements [3]. Group 2: Financial Impact - Following the DOJ announcement, Regeneron's stock price fell by $31.50, or 3.36%, closing at $904.70 on April 12, 2024 [4]. - On October 31, 2024, Regeneron reported third quarter 2024 financial results, showing only a 3% increase in U.S. net sales for Eylea HD and Eylea, with Eylea HD sales at $392 million, missing estimates of $415 million to $425 million [5]. - After the financial results were released, Regeneron's stock price dropped by $84.59, or 9.2%, closing at $838.20 on October 31, 2024 [5].

Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN) ...

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! ...